Intra assay relative bioavailability of two formulations of tacrolimus: Prograf (normal release tablets) and Advagraf (sustained release tablets) for children transplanted kidney [Ensayo intrapaciente de biodisponibilidad relativa de dos formulaciones de tacrolimus: Prograf (comprimidos de liberación normal) y Advagraf (comprimidos de liberación sostenida) en niños trasplantados de riñón]

Trial Profile

Intra assay relative bioavailability of two formulations of tacrolimus: Prograf (normal release tablets) and Advagraf (sustained release tablets) for children transplanted kidney [Ensayo intrapaciente de biodisponibilidad relativa de dos formulaciones de tacrolimus: Prograf (comprimidos de liberación normal) y Advagraf (comprimidos de liberación sostenida) en niños trasplantados de riñón]

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2012

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 20 Nov 2012 Planned End Date changed to 24 Dec 2010.
    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top